• Earlier this month, Twist Bioscience completed a US$300.0 million follow-on common stock offering at US$96.00 per share, shortly after filing for a US$250.0 million raise, alongside reporting third-quarter 2026 sales of US$118.38 million and a loss of US$35.05 million.
• The company also raised its full-year 2026 revenue guidance to US$456.0 million–US$457.0 million and signaled continued sequential growth across key product lines.
• Next, we’ll examine how Twist Bioscience’s upgraded full-year revenue guidance could reshape its existing investment narrative and risk-reward profile.

Uncover the next big thing with 20 elite penny stocks that balance risk and reward.

Twist Bioscience Investment Narrative Recap

To own Twist Bioscience, you need to believe its synthetic DNA platform can translate strong revenue growth into a credible path toward lower losses and, eventually, profitability. The recent US$300.0 million follow-on offering strengthens the balance sheet and may reduce near term financing pressure, but it also highlights ongoing dilution risk as the company remains meaningfully loss making.

The guidance increase to US$456.0 million–US$457.0 million in fiscal 2026 revenue is the key announcement here, because it directly ties to the near term catalyst of execution against higher sales expectations. With Q3 2026 revenue at US$118.38 million and a net loss of US$35.05 million, Twist still must prove it can convert top line growth into margin progress while managing customer concentration and competitive pressures.

Yet behind the upgraded guidance and fresh capital, investors should be aware of the risk that continued losses and dilution could...

Twist Bioscience's narrative projects $753.3 million revenue and $127.9 million earnings by 2029.

Uncover how Twist Bioscience's forecasts yield a $105.30 fair value, a 11% downside to its current price.

Exploring Other Perspectives

Compared with consensus, the most pessimistic analysts were assuming about 15.3% annual revenue growth and no profitability within three years, so this latest equity raise and guidance upgrade could eventually shift both their concerns about rising costs and competition and your view of how realistic those harsher assumptions really are.

Explore 4 other fair value estimates on Twist Bioscience - why the stock might be worth as much as 72% more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Twist Bioscience research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Twist Bioscience research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Twist Bioscience's overall financial health at a glance.

Interested In Other Possibilities?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• AI is about to change healthcare. These 42 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.